Moderna, Inc. (MRNA) FY2024 YTD Q3 P&L / Income Statement

Moderna, Inc. (MRNA) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

2,270,000,000 US dollars

Cost of sales

725,000,000 US dollars

Gross profit (calculated)

1,545,000,000 US dollars

Operating expenses (calculated)

4,244,000,000 US dollars

Loss from operations

negative 2,699,000,000 US dollars

Other income (expense), net (calculated)

276,000,000 US dollars

Income (loss) before income taxes

negative 2,423,000,000 US dollars

Provision for income taxes

18,000,000 US dollars

Net income (loss)

negative 2,441,000,000 US dollars

Licensing and royalty revenue

37,000,000 US dollars

Grant revenue

27,000,000 US dollars

Collaboration revenue

35,000,000 US dollars

Net product sales - UNITED STATES

1,477,000,000 US dollars

Net product sales - Rest of world

413,000,000 US dollars

Net product sales - Europe

281,000,000 US dollars

Research and development

3,421,000,000 US dollars

Selling, general and administrative

823,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.